Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;33(2):e13234.
doi: 10.1111/dth.13234. Epub 2020 Feb 5.

Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options

Mohamad Goldust  1   2   3 , Mario Giulini  2 , Beate Weidenthaler-Barth  2 , Mrinal Gupta  4 , Stephan Grabbe  2 , Hadrian Schepler  2
Affiliations
Review

Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options

Mohamad Goldust et al. Dermatol Ther. 2020 Mar.

Abstract

Angiosarcomas (ASs) are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy or chronic lymphedema. With only 1-5% of all sarcomas, the incidence seems low, but for the affected patient due to the extremely poor prognosis and the limited treatment options, the fate is often inevitable. Radiotherapy, chemotherapy, or "target therapy" have been used in the management of AS, but represent individual case decisions without lasting evidence. Over the past few years, breast-conserving surgery followed by radiation therapy, known as breast-conserving therapy (BCT), is being employed as a standard treatment for early-stage breast cancer, but there has been an increase in reports of AS following BCT. We report two cases of AS following BCT and one case of primary AS involving the lower limb.

Keywords: angiosarcoma; breast-conserving therapy; radiation.

PubMed Disclaimer

References

REFERENCES

    1. Agulnik, M., Yarber, J. L., Okuno, S. H., Von Mehren, M., Jovanovic, B. D., & Brockstein, B. E. (2012). An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Annals of Oncology, 24(1), 257-263.
    1. Billings, S. D., McKenney, J. K., Folpe, A. L., Hardacre, M. C., & Weiss, S. W. (2004). Cutaneous angiosarcoma following breast-conserving surgery and radiation: An analysis of 27 cases. American Journal of Surgical Pathology, 28, 781-788.
    1. Brenn, T., & Fletcher, C. D. (2005). Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: Clinicopathologic analysis of 42 cases. American Journal of Surgical Pathology, 29(8), 983-996.
    1. Chow, W., Amaya, C. N., Rains, S., Chow, M., Dickerson, E. B., & Bryan, B. A. (2015). Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatology, 151(11), 1226-1229.
    1. D'Angelo, S. P., Antonescu, C. R., Kuk, D., Qin, L., Moraco, N., & Carvajal, R. C. (2013). High-risk features in radiation-associated breast angiosarcomas. British Journal of Cancer, 109, 2340-2346.